Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han, Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han

Abstract

Background: The prognosis of patients with unresectable or metastatic biliary tract cancer (BTC) is unacceptably low. This study aimed to determine the efficacy, safety and predictive biomarkers of the immune checkpoint inhibitor nivolumab in combination with chemotherapy in advanced BTCs.

Methods: In this open-label, single-arm, phase II trial, a chemotherapy and immunotherapy combination consisting of gemcitabine 1000 mg/m2, cisplatin 75 mg/m2 and nivolumab 3 mg/kg was administered every 3 weeks for up to six cycles. Maintenance treatment with gemcitabine plus nivolumab was administered to patients achieving disease control following the combination therapy. The primary outcome was the objective response rate. Secondary outcomes included safety, disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). The exploratory objective was to assess biomarkers for predicting clinical response and prognosis.

Results: Thirty-two patients with a median age of 60 (range 27-69) years were enrolled. As of September 31, 2019, the median follow-up was 12.8 (95% CI 10.8 to 14.8) months. Twenty-seven response-evaluable patients received a median of 4 (IQR, 3-6) cycles of combination therapy, of whom 15 (55.6%) patients achieved an objective response, including 5 (18.6%) with a complete response (CR), and the DCR was 92.6%. Of the six patients in cohort A who were resistant to gemcitabine-based or cisplatin-based chemotherapy, one achieved CR and one achieved partial response. Thirteen of 21 chemotherapy-naive patients (61.9%) in cohort B achieved an objective response. The median PFS of all patients in cohorts A+B was 6.1 months. The median OS was 8.5 months, with a 33.3% 12-month OS rate. The most frequent grade 3 or higher adverse events were thrombocytopenia (56%) and neutropenia (22%). Fitness might be a biomarker for predicting clinical response. On-therapy changes in serum soluble FasL, MCP-1 and interferon-γ were correlated with prognosis.

Conclusions: Nivolumab in combination with gemcitabine and cisplatin offers promising efficacy and a manageable safety profile for patients with advanced BTCs.

Trial registration number: NCT03311789.

Keywords: immunology; oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Trial profile. Cis, cisplatin; Gem, gemcitabine.
Figure 2
Figure 2
Characteristics of clinical response and survival. (A) Highest percentage change in the change in target lesion size from baseline in patients from cohort A and cohort B; horizontal dotted lines denote a 30% decrease and 20% increase, indicating objective response and progressive disease, respectively, as per RECIST version 1.1. (B) Percentage change in target lesion tumor size from baseline over time for all evaluable patients, defined as those with baseline tumor assessments and at least one post-treatment assessment. The upper horizontal dotted line indicates disease progression at a 20% increase in the size of target lesions, and the lower dotted line represents an objective response at a 30% decrease in the size of target lesions. (C) Time to response and duration of response in patients from cohort A and cohort B. (D) Kaplan-Meier curves of investigator-assessed progression-free survival in all evaluable patients (upper left). Kaplan-Meier curves of investigator-assessed overall survival in all evaluable patients (upper right). Comparison of the median progression-free survival (mPFS) between cohort A and cohort B (low left). Comparison of the median overall survival (mOS) between cohort A and cohort B (low right). RECIST, Response Evaluation Criteria in Solid Tumors.
Figure 3
Figure 3
Biomarkers for response and prognosis. (A) Correlation of TMB, TNB, heterogeneity, fitness and clinical response between the responding group and the non-responding group. (B) Mutated genes detected by whole-exome sequencing. (C) Kaplan-Meier curves of progression-free survival and overall survival between patients with high TNB and other levels of TNB. (D) Kaplan-Meier curves of progression-free survival of patients who had increased IFN-γ versus those who had decreased IFN-γ, patients who had increased granulysin versus those who had decreased granulysin, patients who had increased MCP-1 versus those who had decreased MCP-1, and patients who had increased sFasL versus those who had decreased sFasL. (E) Kaplan-Meier curves of overall survival of patients who had increased IFN-γ versus those who had decreased IFN-γ, patients who had increased granulysin versus those who had decreased granulysin, patients who had increased MCP-1 versus those who had decreased MCP-1, and patients who had increased sFasL versus those who had decreased sFasL. IFN-γ, interferon-γ; sFasL, soluble FasL; TMB, tumor mutational burden; TNB, tumor neoantigen burden.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. 10.3322/caac.21492
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1789–858. 10.1016/S0140-6736(18)32279-7
    1. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013;11:13–21. 10.1016/j.cgh.2012.09.009
    1. Valle J, Wasan H, Palmer DH, et al. . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81. 10.1056/NEJMoa0908721
    1. Malka D, Cervera P, Foulon S, et al. . Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014;15:819–28. 10.1016/S1470-2045(14)70212-8
    1. Park K, Kim K-P, Park S, et al. . Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol 2017;13:13–20. 10.1111/ajco.12592
    1. Sahai V, Catalano PJ, Zalupski MM, et al. . Nab-Paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:1707–12. 10.1001/jamaoncol.2018.3277
    1. Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol 2017;67:632–44. 10.1016/j.jhep.2017.03.026
    1. Rizvi S, Khan SA, Hallemeier CL, et al. . Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018;15:95–111. 10.1038/nrclinonc.2017.157
    1. Heymach J, Krilov L, Alberg A, et al. . Clinical cancer advances 2018: annual report on progress against cancer from the American Society of clinical oncology. J Clin Oncol 2018;36:1020–44. 10.1200/JCO.2017.77.0446
    1. Martin-Liberal J, Ochoa de Olza M, Hierro C, et al. . The expanding role of immunotherapy. Cancer Treat Rev 2017;54:74–86. 10.1016/j.ctrv.2017.01.008
    1. Bang YJ, Doi T, Braud FD, et al. . 525 safety and efficacy of pembrolizumab (MK-3475) in patients (PTS) with advanced biliary tract cancer: interim results of KEYNOTE-028. Eur J Cancer 2015;51:s112 10.1016/S0959-8049(16)30326-4
    1. DT L, Durham JN, Smith KN, et al. . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.
    1. Silva VWK, Askan G, Daniel TD, et al. . Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 2016;5:62. 10.21037/cco.2016.10.04
    1. Galluzzi L, Buqué A, Kepp O, et al. . Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015;28:690–714. 10.1016/j.ccell.2015.10.012
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. 10.1016/j.ejca.2008.10.026
    1. Łuksza M, Riaz N, Makarov V, et al. . A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 2017;551:517–20. 10.1038/nature24473
    1. Le Roy A, Kempf E, Ackermann F, et al. . Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer 2016;54:172–4. 10.1016/j.ejca.2015.10.073
    1. Shiuan E, Beckermann KE, Ozgun A, et al. . Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017;5:8. 10.1186/s40425-017-0210-0
    1. Kanameishi S, Otsuka A, Nonomura Y, et al. . Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 2016;27:546–7. 10.1093/annonc/mdv580
    1. Rolfes V, Idel C, Pries R, et al. . Pd-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget 2018;9:27460–70. 10.18632/oncotarget.25446
    1. Ueno M, Ikeda M, Morizane C, et al. . Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 2019;4:611–21. 10.1016/S2468-1253(19)30086-X
    1. Di Caro G, Cortese N, Castino GF, et al. . Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2016;65:1710–20. 10.1136/gutjnl-2015-309193
    1. Liu WM, Fowler DW, Smith P, et al. . Pre-Treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115–23. 10.1038/sj.bjc.6605465
    1. Lesterhuis WJ, Salmons J, Nowak AK, et al. . Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8:e61895. 10.1371/journal.pone.0061895
    1. Morisaki T, Hirano T, Koya N, et al. . NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res 2014;34:4529–38.
    1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19:133–50. 10.1038/s41568-019-0116-x
    1. Hellmann MD, Nathanson T, Rizvi H, et al. . Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 2018;33:843–52. 10.1016/j.ccell.2018.03.018
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20. 10.1016/S0140-6736(16)00561-4
    1. Carbone DP, Reck M, Paz-Ares L, et al. . First-Line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376:2415–26. 10.1056/NEJMoa1613493
    1. Hanna GJ, Lizotte P, Cavanaugh M, et al. . Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight 2018;3:1–4. 10.1172/jci.insight.98811
    1. Hellmann MD, Callahan MK, Awad MM, et al. . Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2018;33:853–61. 10.1016/j.ccell.2018.04.001
    1. Goodman AM, Kato S, Bazhenova L, et al. . Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017;16:2598–608. 10.1158/1535-7163.MCT-17-0386
    1. Samstein RM, Lee C-H, Shoushtari AN, et al. . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51:202–6. 10.1038/s41588-018-0312-8
    1. Rosenthal R, Cadieux EL, Salgado R, et al. . Neoantigen-directed immune escape in lung cancer evolution. Nature 2019;567:479–85. 10.1038/s41586-019-1032-7
    1. Le DT, Durham JN, Smith KN, et al. . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13. 10.1126/science.aan6733
    1. Le DT, Uram JN, Wang H, et al. . Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–20. 10.1056/NEJMoa1500596
    1. Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor Treatment—A review from the melanoma perspective and beyond. Front Immunol 2018;9:1474 10.3389/fimmu.2018.01474
    1. Ferrucci PF, Ascierto PA, Pigozzo J, et al. . Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 2016;27:732–8. 10.1093/annonc/mdw016
    1. Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor Treatment-A review from the melanoma perspective and beyond. Front Immunol 2018;9:1474. 10.3389/fimmu.2018.01474
    1. Riaz N, Havel JJ, Makarov V, et al. . Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 2017;171:934–49. 10.1016/j.cell.2017.09.028
    1. Yu H, Chen Z, Ballman KV, et al. . Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma. J Thorac Oncol 2019;14:25–36. 10.1016/j.jtho.2018.09.006
    1. Feun LG, Li Y-Y, Wu C, et al. . Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer 2019;125:3603–14. 10.1002/cncr.32339
    1. Kato Y, Cyon J-C, Yoshimatsu K, et al. . [Efficacy of activated lymphocytes transfer therapy as a novel maker for serum granulysin level with advanced gastric cancer patients]. Gan To Kagaku Ryoho 2008;35:2262–4.
    1. Huang X, Zhang J, Li X, et al. . Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). Int Immunopharmacol 2018;59:127–33. 10.1016/j.intimp.2018.04.011

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever